Varicose veins can be an embarrassing condition that causes patients to avoid shorts and outdoor activities. Recently, the US FDA approved Asclera (polidocanol) injections for the treatment of small types of abnormally swollen or twisted veins called varicose veins.
Many factors such as age, and genetics affect where and how severe your varicose veins may be, and though they are normally on the legs, they can occur in other places on the body. They are a common condition, especially amongst women. Small varicose veins are known as spider veins, which Asclera treats by damaging the cell lining of the blood vessels, causing them to close, and thereby reducing their appearance.
The FDA has approved Asclera to close spider veins (tiny varicose veins less than 1 millimeter in diameter) and reticular veins (those that are 1 to 3 millimeters in diameter). Asclera acts by damaging the cell lining of blood vessels. This causes the blood vessel to close, and it is eventually replaced by other types of tissue.
Common adverse reactions to Asclera include leakage and collection of blood from damaged blood vessels at the injection site (hematoma), bruising, irritation, discoloration, and pain at the injection site.